Author: Rianne van Bentum (Netherlands)
Co-authors:
Purpose
Acute anterior uveitis (AAU), affecting up to 40% of patients with axial spondyloarthritis (axSpA), risks permanent visual deficits if not adequately treated. We report 2-year results from C-VIEW, the first study to prospectively investigate certolizumab pegol (CZP) on AAU in patients with active axSpA at high risk of recurrent AAU.
Setting/Venue
N/A
Methods
C-VIEW (NCT03020992) was a 104-week (96 weeks plus 8-week safety follow-up), open-label, multicentre study. Eligible patients had active axSpA, HLA-B27 positivity and history of recurrent AAU (≥2 AAU flares in total; ≥1 in the year prior to baseline). Patients received CZP 400 mg at Weeks 0/2/4, then 200 mg every 2 weeks to Week 96. The primary efficacy endpoint was the AAU flare event rate during 96 weeks’ CZP versus 2 years pre-baseline.
Results
Of 115 enrolled patients, 89 initiated CZP (male: 63%; radiographic/non-radiographic axSpA: 85%/15%; mean disease duration: 9.1 years); 83 completed Week 96. There was a significant 82% reduction in AAU flare event rate during CZP versus pre-baseline (rate ratio [95% CI]: 0.18 [0.12, 0.28], p<0.001). 100% and 59.6% of patients experienced ≥1 and ≥2 AAU flares pre-baseline, respectively, compared to 20.2% and 11.2% during treatment. Age, sex and axSpA population subgroup analyses were consistent with the primary analysis. There were substantial improvements in axSpA disease activity with no new safety signal identified.
Conlusions
CZP treatment significantly reduced AAU flare event rate in patients with axSpA and a history of AAU, indicating CZP is a suitable treatment option for patients at risk of recurrent AAU.
Financial Disclosure
No declaration of conflicting interest.
Comments
Additional Co-authors: 1. Irene E. van der Horst-Bruinsma - Amsterdam University Medical Centers, location VU Medical Centre, Amsterdam, The Netherlands 2. Rianne E. van Bentum - Amsterdam University Medical Centers, location VU Medical Centre, Amsterdam, The Netherlands 3. Frank D. Verbraak - Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands 4. Atul Deodhar - Oregon Health & Science University, Portland, OR, USA 5. Thomas Rath- St Franziskus-Hospital, Münster, Germany 6. Bengt Hoepken - UCB Pharma, Monheim am Rhein, Germany 7. Oscar Irvin-Sellers - UCB Pharma, Slough, UK 8. Karen Thomas - UCB Pharma, Monheim am Rhein, Germany 9. Lars Bauer - UCB Pharma, Monheim am Rhein, Germany 10. Martin Rudwaleit - Klinikum Bielefeld and Charité Berlin, Germany